



For Immediate Release

David Kaysen Named President & CEO of Sun BioPharma

Healthcare Executive Brings Extensive Clinical & Public Markets Experience to Sun's Management Team

Minneapolis, MN, September 16, 2015- Sun BioPharma, Inc., (OTCPink: SNBP), a biopharmaceutical company developing therapies for the treatment of pancreatic cancer, today announced that David B. Kaysen, a veteran healthcare executive, has been appointed President and Chief Executive Officer as well as a member of the Company's Board of Directors effective immediately. Mr. Kaysen brings to Sun BioPharma more than 25 years of healthcare clinical development, commercial and public company achievements. He joins the Company as its lead development candidate, SBP-101, is expected to begin a Phase 1 clinical trial for the treatment of pancreatic cancer by the end of this year.

Prior to joining Sun, Mr. Kaysen was an advisor and senior executive for several domestic and European growth-oriented privately-held healthcare companies. He currently serves on the Board of Directors of four privately held companies, three of which are in the health care space. From 2006 until 2013 Mr. Kaysen served as President and Chief Executive Officer of Uroplasty, a Twin Cities-based publicly traded global medical device company now part of Cogentix Medical, where he guided the company through successful clinical trials and grew annual sales to \$22 million. Previously, Mr. Kaysen served as President and CEO of Advanced Duplications Services, LLC; President, Chief Executive Officer and a director of Diametrics Medical, Inc. and President, Chief Executive Officer and a director of Rehabicare, Inc.

“Dave’s proven track record leading healthcare companies, specifically in guiding programs through the clinical development process, makes him the ideal executive to lead our company through the next phase of its development,” said Michael Cullen, MD MBA, Executive Chairman of Sun BioPharma. “David’s public company knowledge navigating the equity capital markets and operational experience will be especially valuable as we begin the Phase 1 clinical study of SBP-101 in Australia, later this year.”

“SBP-101 represents a novel approach to treat pancreatic cancer and pancreatitis and has the potential to become a game-changer,” commented Mr. Kaysen. “I look forward to working with Michael and our organization as we execute our plan to move SBP-101 through the clinic to achieve the goal of meeting unmet medical needs while generating value for our shareholders.”

About Sun BioPharma

Sun BioPharma Inc. is a privately-held next-generation biopharmaceutical company developing disruptive therapeutics for serious unmet medical needs. The company’s initial programs are aimed at diseases of the pancreas, including pancreatitis and pancreatic cancer. Sun BioPharma has scientific collaborations with pancreatic disease experts at The Ohio State University, the Fred Hutchinson Cancer Center in Seattle, Translational Genomics (TGen) in Scottsdale, AZ, Cedars Sinai Medical Center in Los Angeles, the University of Minnesota, the Austin Health Cancer Trials Centre and the Box Hill Hospital in Melbourne, Australia and the Ashford Cancer Centre in Adelaide, Australia. Further information can be found at: www.sunbiopharma.com.

Safe Harbor

Statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for Sun BioPharma, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,”

“anticipates,” “expects,” “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the businesses of Sun BioPharma particularly those mentioned in the cautionary statements found in Sun BioPharma’s filings with the Securities and Exchange Commission. Sun BioPharma disclaims any intent or obligation to update these forward-looking statements.